In terms of ATS and the data there, other than a presentation of what data we???ve already seen, can you give us some idea of what else we might see, for example, will we see any kind of robust statistical testing in terms of CAPACITY 1 and CAPACITY 2, so that we can understand just how robust the respective trials were and any kind of explanation in terms of the patient demographics themselves th